Latest News

Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD
Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD

June 20th 2025

Octavio Ramilo, MD, joins us once again to discuss potential benefits of RSV vaccination beyond disease prevention, and to explain how to speak with patients about vaccines and uptake.

Weekly review: Clesrovimab for RSV approved, new dupilumab data, and more
Weekly review: Clesrovimab for RSV approved, new dupilumab data, and more

June 13th 2025

FDA expands glecaprevir/pibrentasvir indication for acute hepatitis C down to 3 years of age | Image credit: Contemporary Pediatrics
FDA expands glecaprevir/pibrentasvir indication for acute hepatitis C down to 3 years of age

June 12th 2025

FDA approves clesrovimab to protect infants during first RSV season | Image Credit: Contemporary Pediatrics
FDA approves clesrovimab to protect infants during first RSV season

June 9th 2025

Six-month IXCHIQ chikungunya vaccine data demonstrates sustained antibody levels | Image Credit: © Monir - © Monir - stock.adobe.com.
Six-month IXCHIQ chikungunya vaccine data demonstrates sustained antibody levels

June 5th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.